Pleximmune^TM

Plexision’s first patented product, the Pleximmune^TM test, predicts the risk of acute cellular rejection after liver or intestine transplantation in children. Cellular rejection, the leading type of rejection after organ transplantation, is mediated by cell-mediated toxicity toward transplanted organs.

The Pleximmune^TM test:

• Is a functional test, which simulates the host-graft interaction.
• Measures the inflammatory response of T-cytotoxic memory lymphocytes to donor cells. T-cytotoxic memory lymphocytes are a type of lymphocyte. Lymphocytes are a type of white blood cell.
• Generates a numeric score called the immunoreactivity index. This index is compared with a rejection-risk threshold developed from testing of over 200 liver or intestine recipients to assign risk.